Roberto Pazo-Cid

9.1k total citations · 2 hit papers
69 papers, 1.4k citations indexed

About

Roberto Pazo-Cid is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Roberto Pazo-Cid has authored 69 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Roberto Pazo-Cid's work include Pancreatic and Hepatic Oncology Research (34 papers), Cancer Genomics and Diagnostics (19 papers) and Gastric Cancer Management and Outcomes (13 papers). Roberto Pazo-Cid is often cited by papers focused on Pancreatic and Hepatic Oncology Research (34 papers), Cancer Genomics and Diagnostics (19 papers) and Gastric Cancer Management and Outcomes (13 papers). Roberto Pazo-Cid collaborates with scholars based in Spain, United States and South Korea. Roberto Pazo-Cid's co-authors include Eric Van Cutsem, Antonio Antón, A. Antón Torres, Teresa Macarulla, Jaffer A. Ajani, Teresa Puértolas, Á. Artal, Joseph Chao, Giuseppe Aprile and María Álvarez and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Roberto Pazo-Cid

64 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

2023 342 citations Kohei Shitara, Florian Lordick et al. profile →
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

2023 185 citations Zev A. Wainberg, Davide Melisi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roberto Pazo-Cid Spain	17	801	553	335	331	295	69	1.4k
Constantin Volovăț Romania	14	781 1.0×	655 1.2×	179 0.5×	272 0.8×	273 0.9×	43	1.3k
Nozomu Fuse Japan	23	747 0.9×	797 1.4×	164 0.5×	410 1.2×	382 1.3×	92	1.6k
Zhehai Wang China	22	1.0k 1.3×	844 1.5×	192 0.6×	445 1.3×	230 0.8×	81	1.7k
Autumn J. McRee United States	15	1.1k 1.4×	579 1.0×	180 0.5×	300 0.9×	343 1.2×	51	1.5k
Haijun Deng China	25	994 1.2×	659 1.2×	611 1.8×	730 2.2×	491 1.7×	72	2.1k
Nong Xu China	18	955 1.2×	799 1.4×	176 0.5×	401 1.2×	441 1.5×	96	1.6k
Andrew Dean Australia	17	1.1k 1.4×	694 1.3×	267 0.8×	262 0.8×	198 0.7×	104	1.6k
Yiyi Yu China	21	741 0.9×	460 0.8×	327 1.0×	447 1.4×	273 0.9×	99	1.4k
Junichiro Watanabe Japan	22	654 0.8×	382 0.7×	279 0.8×	190 0.6×	154 0.5×	126	1.5k

Countries citing papers authored by Roberto Pazo-Cid

Since Specialization

Citations

This map shows the geographic impact of Roberto Pazo-Cid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Pazo-Cid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Pazo-Cid more than expected).

Fields of papers citing papers by Roberto Pazo-Cid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Pazo-Cid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Pazo-Cid. The network helps show where Roberto Pazo-Cid may publish in the future.

Co-authorship network of co-authors of Roberto Pazo-Cid

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Pazo-Cid. A scholar is included among the top collaborators of Roberto Pazo-Cid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Pazo-Cid. Roberto Pazo-Cid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klempner, Samuel J., Roberto Pazo-Cid, Sara Lonardi, et al.. (2025). Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study. PubMed. 7. 100131–100131. 4 indexed citations

Moehler, Markus, Do‐Youn Oh, Ken Kato, et al.. (2025). First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305. Advances in Therapy. 42(5). 2248–2268. 2 indexed citations

Pazo-Cid, Roberto, T. Macarulla Mercadé, Berta Laquente, et al.. (2025). 2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC). Annals of Oncology. 36. S1146–S1147.

Wainberg, Zev A., Davide Melisi, Teresa Macarulla, et al.. (2025). A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Future Oncology. 21(7). 765–774.

Álvarez, Silvia Izquierdo, et al.. (2025). Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management. Journal of Clinical Medicine. 14(2). 367–367. 1 indexed citations

Xu, Jianming, Ken Kato, Yongqian Shu, et al.. (2024). 395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306. Annals of Oncology. 35. S159–S159. 1 indexed citations

Hussein, Maen, Gazala Khan, Sreenivasa R Chandana, et al.. (2024). NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.. Journal of Clinical Oncology. 42(16_suppl). 4136–4136. 2 indexed citations

Méndez, Guillermo, Joseph Chao, Radim Němeček, et al.. (2024). First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. Journal of Clinical Oncology. 42(17). 2080–2093. 27 indexed citations

López, Carlos, Mariona Calvo, Juan Carlos Cámara, et al.. (2024). SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clinical & Translational Oncology. 26(11). 2800–2811. 2 indexed citations

10.

Moehler, Markus, D-Y. Oh, Kazuyoshi Kato, et al.. (2024). 397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305. Annals of Oncology. 35. S160–S161. 7 indexed citations

11.

Cruz‐Correa, Marcia, D-Y. Oh, Ken Kato, et al.. (2024). 1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up. Annals of Oncology. 35. S893–S894. 4 indexed citations

12.

Mercadé, T. Macarulla, Roberto Pazo-Cid, Mark Womack, et al.. (2024). 323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3. Annals of Oncology. 35. S135–S136. 2 indexed citations

13.

Wainberg, Zev A., Davide Melisi, Teresa Macarulla, et al.. (2023). O-1 Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial. Annals of Oncology. 34. S180–S180. 1 indexed citations

14.

Oh, D-Y., H-T. Arkenau, Josep Tabernero, et al.. (2023). 139MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology. 34. S1526–S1527. 3 indexed citations

15.

Ajani, Jaffer A., Florian Lordick, Y-J. Bang, et al.. (2023). LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1322–S1322.

16.

Li, Weiyao, Ángel Celdrán, Pedro Villarejo‐Campos, et al.. (2022). A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy. Journal of Clinical Medicine. 11(24). 7310–7310. 17 indexed citations

17.

Viúdez, A., Emilia Alors‐Pérez, Saioa Goñi, et al.. (2022). Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Cancers. 14(23). 5993–5993. 3 indexed citations

18.

Pazo-Cid, Roberto, et al.. (2021). Fluorescence Liquid Biopsy for Cancer Detection Is Improved by Using Cationic Dendronized Hyperbranched Polymer. International Journal of Molecular Sciences. 22(12). 6501–6501. 6 indexed citations

19.

Martínez‐Trufero, Javier, et al.. (2017). Desmoid-Type Fibromatosis: Who, When, and How to Treat. Current Treatment Options in Oncology. 18(5). 29–29. 55 indexed citations

20.

Pazo-Cid, Roberto & Antonio Antón. (2012). Advanced HER2-positive gastric cancer: Current and future targeted therapies. Critical Reviews in Oncology/Hematology. 85(3). 350–362. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact